Thrivent Financial for Lutherans Grows Stock Holdings in STERIS plc $STE

Thrivent Financial for Lutherans grew its stake in shares of STERIS plc (NYSE:STE) by 49.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 159,864 shares of the medical equipment provider’s stock after acquiring an additional 52,746 shares during the period. Thrivent Financial for Lutherans owned 0.16% of STERIS worth $38,402,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Allworth Financial LP raised its stake in shares of STERIS by 7.3% during the 2nd quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 45 shares during the period. Geneos Wealth Management Inc. grew its holdings in STERIS by 34.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 45 shares in the last quarter. Ashton Thomas Private Wealth LLC increased its position in shares of STERIS by 3.5% during the first quarter. Ashton Thomas Private Wealth LLC now owns 1,611 shares of the medical equipment provider’s stock valued at $365,000 after buying an additional 54 shares during the period. Horizon Investments LLC lifted its holdings in shares of STERIS by 4.7% in the first quarter. Horizon Investments LLC now owns 1,410 shares of the medical equipment provider’s stock worth $320,000 after buying an additional 63 shares in the last quarter. Finally, Berry Wealth Group LP boosted its position in shares of STERIS by 5.3% in the second quarter. Berry Wealth Group LP now owns 1,251 shares of the medical equipment provider’s stock valued at $300,000 after acquiring an additional 63 shares during the period. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $273.50.

Insider Transactions at STERIS

In related news, VP Renato Tamaro sold 5,036 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at approximately $1,466,747.25. This trade represents a 46.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Daniel A. Carestio sold 159 shares of the company’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the sale, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. This represents a 0.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,203 shares of company stock valued at $6,624,667 over the last 90 days. Company insiders own 1.07% of the company’s stock.

STERIS Price Performance

STE stock opened at $254.07 on Tuesday. The firm has a 50 day simple moving average of $251.52 and a two-hundred day simple moving average of $243.89. The stock has a market cap of $24.94 billion, a PE ratio of 36.50 and a beta of 1.01. STERIS plc has a one year low of $200.98 and a one year high of $268.60. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter last year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. On average, analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, November 18th. STERIS’s dividend payout ratio is presently 36.21%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.